The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Site Search
Showing 1 - 4 of 4 results
Press Release
|
March 29, 2022
|
4 min read
New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease
Press Release
|
April 19, 2022
|
3 min read
Funding will support preclinical research and early-stage clinical trials
Press Release
|
Jan. 10, 2023
|
3 min read
Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab
Press Release
|
June 21, 2022
|
4 min read